Custom Epithelial Organoid Services

Start with the Surface Your Experiment Must Reach

Epithelial polarity determines what a test article, microorganism, tracer, or cytokine can contact. In a matrix-embedded basal-out organoid, the basolateral surface faces the surrounding matrix while the apical membrane encloses an internal lumen. This geometry supports three-dimensional growth and tissue organization, but direct apical exposure may require microinjection. Removing the extracellular matrix and culturing organoids in suspension can reverse polarity so the apical surface faces the medium. Dissociating an organoid and seeding its cells on a permeable support can instead create a polarized monolayer with independently accessible apical and basolateral compartments.

For a solution-level view that connects model selection, characterization, functional studies, and sequencing readouts, see Organoid Research and Sequencing Solutions.

These formats are not interchangeable. A monolayer is appropriate when directional exposure, transepithelial electrical resistance, or tracer flux is central to the endpoint. An apical-out organoid is useful when direct access should remain compatible with a three-dimensional structure. A basal-out organoid may be preferable when tissue architecture, growth, or luminal accumulation is more important than external access. Microinjection preserves the enclosed lumen but adds technical variability and throughput constraints. We therefore begin with the surface that must be reached, the biological structure that must be preserved, and the measurement that must remain interpretable.

Best for

• Studies requiring controlled apical, basolateral, or luminal exposure in an epithelial organoid system.
• Barrier and permeability research that combines electrical, tracer, imaging, and molecular evidence.
• Mechanistic inflammatory bowel disease research using organoid-derived epithelial models and project-defined challenges.
• Research-use CFTR function studies using swelling, imaging, and appropriate controls.
• Host–microbe or host–metabolite experiments in which exposure route, oxygen, and epithelial viability must be planned together.

Not for

• Diagnostic testing, therapy selection, patient stratification, clinical decision-making, or clinical trials.
• Calling a barrier intact from morphology or transepithelial resistance alone.
• Assuming apical-out conversion preserves every feature of the original matrix-embedded model.
• Using one universal acceptance threshold across tissues, donors, membranes, media, and instruments.
• Interpreting organoid swelling as CFTR-specific without vehicle, assay-performance, and pathway-relevant controls.

Qualify Polarity, Lineage, and Barrier Before Perturbation

A confluent surface is not necessarily a mature or selective barrier. Likewise, a spherical organoid does not prove that the intended surface faces outward. The acceptance package is built from independent evidence chosen for the model and tissue. Polarity may be reviewed through apical and basolateral marker localization, brush-border or ciliary features where relevant, and junctional organization. Lineage evidence uses a project-qualified panel rather than a fixed list that assumes every epithelial tissue should contain the same cell types.

For monolayers, electrical resistance provides a rapid longitudinal signal, but it is influenced by membrane area, temperature, medium, electrode geometry, blank correction, and the intrinsic properties of the tissue. A project-specific plateau is more defensible than a universal cutoff. Fluorescent tracer flux adds a direct permeability dimension, while immunofluorescence can show whether selected tight-junction proteins form continuous or disrupted patterns. Morphology and viability help distinguish barrier opening from generalized cell loss. The model is accepted only when the agreed measurements form a coherent pattern.

• Polarity: exterior versus interior localization of selected apical and basolateral features.
• Junction organization: continuity and localization of project-selected markers such as ZO-1, occludin, or claudins.
• Barrier function: blank-corrected resistance trends, tracer passage, and stability across the planned experimental window.
• Cell composition: tissue-appropriate epithelial lineage markers and, when needed, RNA-based composition analysis.
• Model health: confluence or morphology, viability, growth history, passage, and handling deviations.

Acceptance criteria are agreed before the perturbation begins. If electrical resistance rises while permeability, morphology, or junction imaging shows a conflicting pattern, the discrepancy is investigated rather than averaged into a single score.

Measure CFTR-Dependent Fluid Transport with Assay Controls

Forskolin-induced swelling is an imaging-based research assay in which cyclic-AMP stimulation activates epithelial ion transport and fluid enters the organoid lumen. The measured change depends on CFTR activity, but it also depends on starting size, morphology, lumen state, passage, culture condition, matrix, imaging interval, segmentation, and the dynamic range of the selected model. A swelling trace is therefore interpreted within a controlled assay rather than as a stand-alone biological verdict.

The design begins with a compatible epithelial source and an agreed perturbation scheme. Vehicle controls define baseline growth or drift; a reference control demonstrates that the imaging and analysis pipeline can detect a response; and a pathway-relevant inhibitor or comparator can help test whether the observed signal behaves as expected. Time-resolved images are retained, segmentation rules are documented, and normalized area or volume trajectories are reported with replicate-level data. Saturated or poorly focused organoids are handled under predefined review rules rather than selectively removed after the result is known.

CFTR assays on this page are limited to research-use functional studies, assay development, and mechanistic compound evaluation. They are not offered for diagnosis, clinical eligibility, therapy selection, or prediction of individual patient outcome. When genetic context is important, DNA validation can be linked to the assay design, while RNA sequencing can examine broader epithelial responses; neither replaces the functional swelling measurement.

Run a Gated Workflow from Conversion to Integrated Analysis

The workflow protects limited primary material by qualifying the interface before scaling the perturbation matrix. The model does not advance simply because it can be cultured.

Lock the epithelial interface and its acceptance criteria before the experimental matrix expands.

1. Question and surface definition. Identify the surface that must be exposed, the architecture that must be retained, the primary endpoint, and the evidence boundary.
2. Starting-material review. Document tissue or organoid source, passage, preservation, culture history, available quantity, lineage evidence, contamination status, and transport constraints.
3. Format feasibility. Test the selected basal-out, apical-out, microinjected, monolayer, or air–liquid interface route at a scale appropriate to the material.
4. Qualification gate. Review polarity, confluence or architecture, viability, lineage markers, junction organization, resistance or permeability where relevant, and control separation.
5. Design lock and perturbation. Finalize compartment, dose or exposure logic, time points, biological and technical replication, controls, sampling order, and exclusion rules.
6. Functional and molecular readouts. Collect imaging, barrier, permeability, mediator, CFTR, microbial, or other project-defined endpoints and preserve matched material for sequencing.
7. Integrated reporting. Align sample metadata, raw and processed measurements, QC, sequencing outputs, limitations, and next-study recommendations without extending conclusions beyond the tested model.

Connect Functional Evidence with Sequencing

Sequencing is most informative when it is anchored to a functional state. Bulk RNA sequencing can compare pathway-level changes across a controlled condition matrix and is efficient when the epithelial population is sufficiently defined. Single-cell RNA sequencing can resolve cell-type composition and state changes when heterogeneous epithelial lineages are important, but dissociation may alter fragile populations and remove spatial information. The choice follows the biological ambiguity that must be resolved.

Samples are aligned to functional time points, not collected as an unrelated endpoint. A barrier experiment may pair RNA extraction with resistance and permeability measurements from matched wells. A CFTR study may use sequencing to characterize broader epithelial responses while keeping swelling as the functional endpoint. A host–microbe experiment may require separate host and microbial workflows to avoid confusing RNA origin, extraction bias, and normalization. The analysis plan records biological replicates, batch structure, comparisons, covariates, and the unit of inference before sequencing begins.

Related CD Genomics capabilities can be connected when the project requires them: organoid sequencing services for integrated bulk, single-cell, and spatial planning; single-cell RNA sequencing for epithelial composition and state; organoid characterization services for morphology, marker, and genomic evidence; and organoid model development services when a qualified starting model must first be established. These links support the study architecture without turning the page into a catalogue of unrelated assays.